A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple ianalumab doses administered subcutaneously in patients with moderate to severe primary Sjogren's Syndrome
Latest Information Update: 02 Jan 2024
At a glance
- Drugs Ianalumab (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 15 Nov 2023 Results assessing dose dependent modulation of a B cell protein signature by Ianalumab in patients with Sjogren's-syndrome presented at the ACR Convergence 2023
- 03 Dec 2021 Results published in the Lancet.
- 24 Nov 2021 Status changed from active, no longer recruiting to completed.